Beijing Leadman BiochemistryLtd Past Earnings Performance
Past criteria checks 1/6
Beijing Leadman BiochemistryLtd's earnings have been declining at an average annual rate of -20.6%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 1.9% per year. Beijing Leadman BiochemistryLtd's return on equity is 0.6%, and it has net margins of 1%.
Key information
-20.6%
Earnings growth rate
-16.2%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 1.9% |
| Return on equity | 0.6% |
| Net Margin | 1.0% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Beijing Leadman BiochemistryLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 448 | 4 | 196 | 37 |
| 31 Dec 23 | 462 | 15 | 195 | 37 |
| 30 Sep 23 | 504 | -67 | 216 | 32 |
| 30 Jun 23 | 559 | -64 | 228 | 35 |
| 31 Mar 23 | 623 | -60 | 233 | 34 |
| 01 Jan 23 | 706 | -56 | 233 | 35 |
| 30 Sep 22 | 692 | 28 | 203 | 37 |
| 30 Jun 22 | 693 | 33 | 191 | 34 |
| 31 Mar 22 | 640 | 28 | 187 | 33 |
| 01 Jan 22 | 564 | 22 | 184 | 33 |
| 30 Sep 21 | 561 | -27 | 256 | 31 |
| 30 Jun 21 | 541 | -31 | 257 | 31 |
| 31 Mar 21 | 531 | -29 | 244 | 37 |
| 31 Dec 20 | 472 | -51 | 231 | 38 |
| 30 Sep 20 | 478 | 1 | 168 | 43 |
| 30 Jun 20 | 440 | -8 | 156 | 47 |
| 31 Mar 20 | 454 | -15 | 170 | 47 |
| 31 Dec 19 | 515 | 6 | 179 | 48 |
| 30 Sep 19 | 493 | -10 | 197 | 49 |
| 30 Jun 19 | 563 | 10 | 197 | 45 |
| 31 Mar 19 | 600 | 28 | 196 | 43 |
| 31 Dec 18 | 655 | 40 | 196 | 40 |
| 30 Sep 18 | 711 | 78 | 169 | 40 |
| 30 Jun 18 | 663 | 71 | 152 | 55 |
| 31 Mar 18 | 634 | 75 | 142 | 46 |
| 31 Dec 17 | 576 | 73 | 144 | 37 |
| 30 Sep 17 | 538 | 79 | 152 | 25 |
| 30 Jun 17 | 532 | 75 | 172 | 0 |
| 31 Mar 17 | 521 | 68 | 180 | 0 |
| 31 Dec 16 | 533 | 70 | 181 | 0 |
| 30 Sep 16 | 618 | 126 | 169 | 0 |
| 30 Jun 16 | 639 | 144 | 175 | 0 |
| 31 Mar 16 | 660 | 160 | 161 | 0 |
| 31 Dec 15 | 682 | 157 | 167 | 0 |
| 30 Sep 15 | 682 | 141 | 177 | 0 |
| 30 Jun 15 | 641 | 133 | 166 | 0 |
| 31 Mar 15 | 607 | 131 | 165 | 0 |
| 31 Dec 14 | 537 | 128 | 149 | 0 |
| 30 Sep 14 | 373 | 80 | 116 | 0 |
| 30 Jun 14 | 363 | 91 | 109 | 0 |
| 31 Mar 14 | 342 | 99 | 101 | 0 |
| 31 Dec 13 | 344 | 110 | 93 | 0 |
| 30 Sep 13 | 366 | 120 | 93 | 0 |
| 30 Jun 13 | 351 | 112 | 90 | 0 |
Quality Earnings: 300289 has a large one-off loss of CN¥10.0M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300289 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300289's earnings have declined by 20.6% per year over the past 5 years.
Accelerating Growth: 300289 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 300289 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: 300289's Return on Equity (0.6%) is considered low.